United States Targeted Therapy DataM Market Intelligence Competitive Landscape & Forecast to 2025 | Industry Report

DataM Intelligence unveils its latest report on the "Targeted Therapy Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

For example, F. Hoffmann-La Roche Ltd, a major player in the targeted therapy market, earned 33.71% of its revenue from the U.S., driven by sales of its HER2 inhibitors portfolio (total sales: US$ 9,928.20 million; U.S. sales: US$ 3,347.29 million).

According to the International Agency for Research on Cancer, there were approximately 20 million new cancer cases worldwide in 2022, with projections rising to about 24.1 million by 2030 and 29.9 million by 2040. For example, the targeted therapy drug trastuzumab, marketed as Enhertu, costs around US$ 3,142.90 per injection vial, imposing a substantial financial burden on patients, healthcare systems, and insurers, HER2, EGFR, VEGF, or CD antigens

These drugs, including Trastuzumab (Herceptin), Pertuzumab (Perjeta), Trastuzumab deruxtecan (Enhertu), and Trastuzumab emtansine (Kadcyla), rank among the top-selling targeted cancer therapies. Acting as targeted therapeutics, they are categorized into VEGF inhibitors, CD antigen-targeted mAbs, EGFR inhibitors, HER2 inhibitors, and more. These monoclonal antibodies are used to treat a variety of cancers, including breast, colorectal, leukemia, gynecological, lung, liver, and head and neck cancers.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/targeted-therapy-market?kb

List of Top Key Player:

F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca, Eisai Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company., Incyte, Eli Lilly and Company, and Exelixis, Inc., among others.

Industry Developments:

In May 2025, the U.S. FDA granted accelerated approval to EMRELIS (telisotuzumab vedotin-tllv) by AbbVie for adults with locally advanced or metastatic non-squamous NSCLC overexpressing c-Met after prior therapy.

In March 2025, Genmab A/S announced Japan's approval of TIVDAK (tisotumab vedotin) for advanced or recurrent cervical cancer post-chemotherapy.

In October 2024, Genentech (Roche Group) received FDA approval for Itovebi (inavolisib) with palbociclib and fulvestrant to treat endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Forecast Projection:

The Global Targeted Therapy Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Targeted Therapy Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=targeted-therapy-market

Key Segmentation:

Monoclonal antibodies held 62.5% of market share in 2024

By Type: Monoclonal Antibodies, VEGF Inhibitors, Antibody Drug Conjugates, CD Antigen-Targeted mAbs, EGFR Inhibitors, HER2 Inhibitors, Others, Small Molecules, PARP Inhibitors, Tyrosine Kinase Inhibitors, BRAF/MEK inhibitors, CDK Inhibitors, Others

By Indication: Leukemia, Breast Cancer, Lung Cancer, GI Cancers, Melanoma, Others

By Route of Administration: Oral, Parenteral

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Targeted Therapy Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/targeted-therapy-market?kb

FAQ's

Q1: What is the current size of the Targeted Therapy Market and its future potential?

A: The Targeted Therapy Market was valued at US$ 79.18 billion in 2024 and is projected to surge to US$ 147.16 billion by 2033

Q2: How fast is the Targeted Therapy Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 7.2% between 2025 and 2032, signaling strong global growth and investment potential.

Q3: Which regions are dominating the Targeted Therapy Market and which are fastest-growing?

A: North America dominating the Targeted Therapy market.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.